JP2009528070A - 膵臓癌に関連するマイクロｒｎａ発現プロファイル - Google Patents
膵臓癌に関連するマイクロｒｎａ発現プロファイル Download PDFInfo
- Publication number
- JP2009528070A JP2009528070A JP2008557519A JP2008557519A JP2009528070A JP 2009528070 A JP2009528070 A JP 2009528070A JP 2008557519 A JP2008557519 A JP 2008557519A JP 2008557519 A JP2008557519 A JP 2008557519A JP 2009528070 A JP2009528070 A JP 2009528070A
- Authority
- JP
- Japan
- Prior art keywords
- mir
- gene product
- pancreatic cancer
- subject
- mir gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 184
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 183
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 167
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 167
- 230000014509 gene expression Effects 0.000 title claims description 250
- 108700011259 MicroRNAs Proteins 0.000 title description 65
- 108091070501 miRNA Proteins 0.000 claims abstract description 581
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 439
- 238000000034 method Methods 0.000 claims abstract description 245
- 210000000496 pancreas Anatomy 0.000 claims abstract description 67
- 239000012472 biological sample Substances 0.000 claims abstract description 61
- 239000013068 control sample Substances 0.000 claims abstract description 31
- 239000002679 microRNA Substances 0.000 claims description 206
- 206010028980 Neoplasm Diseases 0.000 claims description 114
- 238000012360 testing method Methods 0.000 claims description 108
- 239000000523 sample Substances 0.000 claims description 106
- 150000007523 nucleic acids Chemical class 0.000 claims description 92
- 239000002243 precursor Substances 0.000 claims description 83
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 72
- 102000039446 nucleic acids Human genes 0.000 claims description 68
- 108020004707 nucleic acids Proteins 0.000 claims description 68
- -1 MIR-130a-P Proteins 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 54
- 230000002401 inhibitory effect Effects 0.000 claims description 46
- 230000000295 complement effect Effects 0.000 claims description 38
- 238000003556 assay Methods 0.000 claims description 36
- 238000009396 hybridization Methods 0.000 claims description 30
- 230000001965 increasing effect Effects 0.000 claims description 30
- 108020004459 Small interfering RNA Proteins 0.000 claims description 29
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 27
- 108091028049 Mir-221 microRNA Proteins 0.000 claims description 26
- 108091033773 MiR-155 Proteins 0.000 claims description 25
- 230000001105 regulatory effect Effects 0.000 claims description 24
- 239000004055 small Interfering RNA Substances 0.000 claims description 23
- 108091034117 Oligonucleotide Proteins 0.000 claims description 22
- 108091074563 miR-301-1 stem-loop Proteins 0.000 claims description 22
- 108091034144 miR-301-2 stem-loop Proteins 0.000 claims description 22
- 230000003321 amplification Effects 0.000 claims description 21
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 21
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims description 21
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims description 21
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 21
- 239000013603 viral vector Substances 0.000 claims description 21
- 108091028108 MiR-212 Proteins 0.000 claims description 20
- 108091031103 miR-181a stem-loop Proteins 0.000 claims description 20
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 claims description 20
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 claims description 20
- 108091053935 miR-212 stem-loop Proteins 0.000 claims description 20
- 108091028397 miR-212-1 stem-loop Proteins 0.000 claims description 20
- 108091028945 miR-212-2 stem-loop Proteins 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 108091093189 Mir-375 Proteins 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 19
- 108091042844 let-7i stem-loop Proteins 0.000 claims description 19
- 239000013612 plasmid Substances 0.000 claims description 19
- 238000011269 treatment regimen Methods 0.000 claims description 19
- 108091007423 let-7b Proteins 0.000 claims description 18
- 108091033753 let-7d stem-loop Proteins 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 108091029710 let-7f-1 stem-loop Proteins 0.000 claims description 16
- 238000000636 Northern blotting Methods 0.000 claims description 13
- 108091007772 MIRLET7C Proteins 0.000 claims description 12
- 108091028080 MiR-132 Proteins 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 108091092072 miR-100 stem-loop Proteins 0.000 claims description 12
- 108091029379 miR-139 stem-loop Proteins 0.000 claims description 12
- 108091065218 miR-218-1 stem-loop Proteins 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 108091084619 miR-125b-1 stem-loop Proteins 0.000 claims description 11
- 108091092367 miR-196a-2 stem-loop Proteins 0.000 claims description 11
- 108090000994 Catalytic RNA Proteins 0.000 claims description 10
- 102000053642 Catalytic RNA Human genes 0.000 claims description 10
- 108091028066 Mir-126 Proteins 0.000 claims description 10
- 238000007901 in situ hybridization Methods 0.000 claims description 10
- 108091037426 miR-152 stem-loop Proteins 0.000 claims description 10
- 108091088856 miR-345 stem-loop Proteins 0.000 claims description 10
- 108091057414 miR-376 stem-loop Proteins 0.000 claims description 10
- 108091092562 ribozyme Proteins 0.000 claims description 10
- 108091080933 Mir-192/215 microRNA precursor Proteins 0.000 claims description 9
- 238000007850 in situ PCR Methods 0.000 claims description 9
- 108091077112 miR-128a stem-loop Proteins 0.000 claims description 9
- 108091047467 miR-136 stem-loop Proteins 0.000 claims description 9
- 108091088730 miR-215 stem-loop Proteins 0.000 claims description 9
- 108091029997 miR-328 stem-loop Proteins 0.000 claims description 9
- 108091030938 miR-424 stem-loop Proteins 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 108091087125 miR-376a stem-loop Proteins 0.000 claims description 8
- 108091073138 miR-376a-3 stem-loop Proteins 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 230000001093 anti-cancer Effects 0.000 claims description 7
- 108091050539 miR-107 stem-loop Proteins 0.000 claims description 7
- 108091064138 miR-129-2 stem-loop Proteins 0.000 claims description 7
- 108091079016 miR-133b Proteins 0.000 claims description 7
- 108091043162 miR-133b stem-loop Proteins 0.000 claims description 7
- 108091031479 miR-204 stem-loop Proteins 0.000 claims description 7
- 108091032382 miR-204-1 stem-loop Proteins 0.000 claims description 7
- 108091085803 miR-204-2 stem-loop Proteins 0.000 claims description 7
- 108091089766 miR-204-3 stem-loop Proteins 0.000 claims description 7
- 108091073500 miR-204-4 stem-loop Proteins 0.000 claims description 7
- 108091053626 miR-204-5 stem-loop Proteins 0.000 claims description 7
- 108091090692 miR-337 stem-loop Proteins 0.000 claims description 7
- 108091048468 miR-383 stem-loop Proteins 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 108091040651 miR-371 stem-loop Proteins 0.000 claims description 6
- 102000006382 Ribonucleases Human genes 0.000 claims description 5
- 108010083644 Ribonucleases Proteins 0.000 claims description 5
- 229940124447 delivery agent Drugs 0.000 claims description 5
- 108091062637 miR-367 stem-loop Proteins 0.000 claims description 5
- 230000030279 gene silencing Effects 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 210000001819 pancreatic juice Anatomy 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 108091091360 miR-125b stem-loop Proteins 0.000 claims description 3
- 238000010208 microarray analysis Methods 0.000 claims description 3
- 101000798869 Escherichia phage Mu DDE-recombinase A Proteins 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 108091086416 miR-192 stem-loop Proteins 0.000 claims description 2
- 108091048308 miR-210 stem-loop Proteins 0.000 claims description 2
- 108091053185 miR-302d stem-loop Proteins 0.000 claims description 2
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims description 2
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims description 2
- 108091037240 miR-423 stem-loop Proteins 0.000 claims description 2
- 230000001124 posttranscriptional effect Effects 0.000 claims description 2
- 238000010240 RT-PCR analysis Methods 0.000 claims 4
- 108091063986 let-7f stem-loop Proteins 0.000 claims 2
- 108091064825 miR-181c stem-loop Proteins 0.000 claims 2
- 108091044400 miR-181c-1 stem-loop Proteins 0.000 claims 2
- 108091048818 miR-181c-2 stem-loop Proteins 0.000 claims 2
- 108091032779 miR-181c-3 stem-loop Proteins 0.000 claims 2
- 108091054980 miR-218-2 stem-loop Proteins 0.000 claims 2
- 108091048857 miR-24-1 stem-loop Proteins 0.000 claims 1
- 108091046260 miR-41 stem-loop Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 110
- 210000001519 tissue Anatomy 0.000 description 83
- 150000001875 compounds Chemical class 0.000 description 46
- 239000002502 liposome Substances 0.000 description 33
- 230000000875 corresponding effect Effects 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 238000003753 real-time PCR Methods 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 210000004881 tumor cell Anatomy 0.000 description 17
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 16
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 15
- 108091062762 miR-21 stem-loop Proteins 0.000 description 15
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 15
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 15
- 108020004463 18S ribosomal RNA Proteins 0.000 description 14
- 229920002401 polyacrylamide Polymers 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 13
- 206010033649 Pancreatitis chronic Diseases 0.000 description 13
- 230000014207 opsonization Effects 0.000 description 12
- 238000002493 microarray Methods 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 238000012549 training Methods 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 206010033645 Pancreatitis Diseases 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000010195 expression analysis Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 101710163270 Nuclease Proteins 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108091007428 primary miRNA Proteins 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229920001451 polypropylene glycol Polymers 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000006607 hypermethylation Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 108091080321 miR-222 stem-loop Proteins 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108091007773 MIR100 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002074 deregulated effect Effects 0.000 description 4
- 230000001973 epigenetic effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 208000016222 Pancreatic disease Diseases 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000007417 hierarchical cluster analysis Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108091091751 miR-17 stem-loop Proteins 0.000 description 3
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 3
- 210000000277 pancreatic duct Anatomy 0.000 description 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000003253 miRNA assay Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FYBLWUVZITWWEZ-UHFFFAOYSA-N Cl.[Ca] Chemical compound Cl.[Ca] FYBLWUVZITWWEZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091027766 Mir-143 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- MMXKIWIWQPKTIK-KPRKPIBOSA-N [(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2r,3s,5r)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)[C@@H](O)C1 MMXKIWIWQPKTIK-KPRKPIBOSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- BHRQIJRLOVHRKH-UHFFFAOYSA-L calcium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;hydron Chemical compound [Ca+2].OC(=O)CN(CC(O)=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O BHRQIJRLOVHRKH-UHFFFAOYSA-L 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000001001 laser micro-dissection Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108091053410 let-7 family Proteins 0.000 description 1
- 108091023663 let-7 stem-loop Proteins 0.000 description 1
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 1
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091027034 miR-148a stem-loop Proteins 0.000 description 1
- 108091074057 miR-16-1 stem-loop Proteins 0.000 description 1
- 108091027698 miR-18-1 stem-loop Proteins 0.000 description 1
- 108091090961 miR-18-2 stem-loop Proteins 0.000 description 1
- 108091059105 miR-216-1 stem-loop Proteins 0.000 description 1
- 108091045470 miR-216-2 stem-loop Proteins 0.000 description 1
- 108091035328 miR-217 stem-loop Proteins 0.000 description 1
- 108091039135 miR-217-1 stem-loop Proteins 0.000 description 1
- 108091029206 miR-217-2 stem-loop Proteins 0.000 description 1
- 108091023818 miR-7 stem-loop Proteins 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000010656 regulation of insulin secretion Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 102220275940 rs1555937015 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940073585 tromethamine hydrochloride Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77827106P | 2006-03-02 | 2006-03-02 | |
| PCT/US2007/063208 WO2007103808A2 (en) | 2006-03-02 | 2007-03-02 | Microrna expression profile associated with pancreatic cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012188756A Division JP5841024B2 (ja) | 2006-03-02 | 2012-08-29 | 膵臓癌に関連するマイクロｒｎａ発現プロファイル |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009528070A true JP2009528070A (ja) | 2009-08-06 |
| JP2009528070A5 JP2009528070A5 (enExample) | 2011-04-21 |
Family
ID=38475730
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557519A Pending JP2009528070A (ja) | 2006-03-02 | 2007-03-02 | 膵臓癌に関連するマイクロｒｎａ発現プロファイル |
| JP2012188756A Expired - Fee Related JP5841024B2 (ja) | 2006-03-02 | 2012-08-29 | 膵臓癌に関連するマイクロｒｎａ発現プロファイル |
| JP2013023199A Pending JP2013081483A (ja) | 2006-03-02 | 2013-02-08 | 膵臓癌に関連するマイクロｒｎａ発現プロファイル |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012188756A Expired - Fee Related JP5841024B2 (ja) | 2006-03-02 | 2012-08-29 | 膵臓癌に関連するマイクロｒｎａ発現プロファイル |
| JP2013023199A Pending JP2013081483A (ja) | 2006-03-02 | 2013-02-08 | 膵臓癌に関連するマイクロｒｎａ発現プロファイル |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20100286232A1 (enExample) |
| EP (6) | EP2522748A1 (enExample) |
| JP (3) | JP2009528070A (enExample) |
| AU (1) | AU2007223311C1 (enExample) |
| CA (1) | CA2638844C (enExample) |
| ES (1) | ES2448491T3 (enExample) |
| WO (1) | WO2007103808A2 (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015107091A (ja) * | 2013-12-05 | 2015-06-11 | 東レ株式会社 | 膵臓がんの検出キット及び検出方法 |
| JP2016123340A (ja) * | 2014-12-26 | 2016-07-11 | 株式会社エバンス | 膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤 |
| KR20170010856A (ko) * | 2014-05-30 | 2017-02-01 | 도레이 카부시키가이샤 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| WO2019117269A1 (ja) | 2017-12-13 | 2019-06-20 | 国立大学法人広島大学 | 膵がんの検出を補助する方法 |
| JP2020120674A (ja) * | 2012-12-06 | 2020-08-13 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ | Ｃｒｉｓｐｒに基づくゲノム修飾および制御 |
| JPWO2022014670A1 (enExample) * | 2020-07-16 | 2022-01-20 | ||
| US12098430B2 (en) | 2016-03-31 | 2024-09-24 | Toray Industries, Inc. | Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471924A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US8592384B2 (en) | 2005-04-04 | 2013-11-26 | The Board Of Regents Of The University Of Texas System | Micro-RNA's that regulate muscle cells |
| CA2664383C (en) * | 2006-09-19 | 2017-08-22 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| CN101827941B (zh) * | 2007-04-30 | 2014-07-16 | 俄亥俄州立大学研究基金会 | 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法 |
| US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| WO2009062169A2 (en) | 2007-11-09 | 2009-05-14 | The Board Of Regents Of The University Of Texas System | Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
| WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009117418A2 (en) | 2008-03-17 | 2009-09-24 | The Board Of Regents Of The University Of Texas System | Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration |
| US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| JP2012507300A (ja) | 2008-10-30 | 2012-03-29 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Ｒｎａパターンを評価する方法 |
| WO2010054386A2 (en) * | 2008-11-10 | 2010-05-14 | Battelle Memorial Institute | Methods, compositions, and devices utilizing microrna to determine physiological conditions |
| EP2350320A4 (en) | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES |
| US9074206B2 (en) | 2008-11-13 | 2015-07-07 | Fudan University | Compositions and methods for micro-RNA expression profiling of colorectal cancer |
| AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| WO2011150855A1 (en) * | 2010-06-04 | 2011-12-08 | Fudan University | Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma |
| EP2591106A1 (en) | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| CA2812650C (en) * | 2010-09-27 | 2019-11-05 | Sabanci Universitesi | Use of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
| US9850541B2 (en) | 2011-12-19 | 2017-12-26 | Valley Health System | Methods and kits for detecting subjects at risk of having cancer |
| WO2013101783A2 (en) | 2011-12-30 | 2013-07-04 | Bio-Rad Laboratories, Inc. | Methods and compositions for performing nucleic acid amplification reactions |
| US9334498B2 (en) | 2012-05-10 | 2016-05-10 | Uab Research Foundation | Methods and compositions for modulating MIR-204 activity |
| US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
| US20150344961A1 (en) * | 2012-09-11 | 2015-12-03 | New York University | Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| EP3434774A1 (en) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| KR101501562B1 (ko) * | 2013-04-05 | 2015-03-11 | 연세대학교 산학협력단 | 췌장암 진단 마커를 검출하는 방법 |
| US20150018230A1 (en) * | 2013-06-11 | 2015-01-15 | Indiana University Research And Technology Corp. | PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA |
| EP3108012A4 (en) | 2014-02-18 | 2017-10-11 | Baylor Research Institute | Mir-320e and colorectal cancer |
| WO2015133477A1 (ja) | 2014-03-04 | 2015-09-11 | 国立大学法人広島大学 | 膵がんの検出を補助する方法 |
| US9623040B2 (en) | 2014-07-14 | 2017-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Immunomodulation by controlling expression levels of microRNAs in dendritic cells |
| EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| PL3458083T3 (pl) | 2016-05-18 | 2023-03-13 | Modernatx, Inc. | Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania |
| EP3468537A1 (en) | 2016-06-14 | 2019-04-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| JP2019518063A (ja) * | 2016-06-20 | 2019-06-27 | クラ オンコロジー， インコーポレイテッド | Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置 |
| CA3029119A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
| WO2018002762A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders |
| US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
| EP4650364A3 (en) | 2016-07-06 | 2026-01-21 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| EP3481857B1 (en) | 2016-07-06 | 2026-02-11 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| CA3042015A1 (en) | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MX2019009070A (es) | 2017-02-01 | 2019-10-30 | Modernatx Inc | Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. |
| WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
| AU2018224387B2 (en) | 2017-02-22 | 2024-08-08 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| WO2018154439A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
| EP3585899A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders |
| WO2018154418A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
| US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| AU2018301704A1 (en) | 2017-07-14 | 2020-03-05 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3714055A1 (en) | 2017-11-21 | 2020-09-30 | CRISPR Therapeutics AG | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| AU2018393050A1 (en) | 2017-12-21 | 2020-06-18 | Bayer Healthcare Llc | Materials and methods for treatment of Usher Syndrome Type 2A |
| US20190314291A1 (en) | 2018-01-30 | 2019-10-17 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| US20210163928A1 (en) | 2018-04-11 | 2021-06-03 | Modernatx, Inc. | Messenger rna comprising functional rna elements |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| BR112021017744A2 (pt) | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| WO2020218489A1 (ja) * | 2019-04-26 | 2020-10-29 | 国立大学法人大阪大学 | トンネル電流を使用したマイクロｒｎａ解析 |
| MA56517A (fr) | 2019-06-24 | 2022-04-27 | Modernatx Inc | Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations |
| EP3987027A1 (en) | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Endonuclease-resistant messenger rna and uses thereof |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US20230285297A1 (en) | 2020-01-31 | 2023-09-14 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| US11965162B2 (en) * | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| JP2023535225A (ja) | 2020-07-24 | 2023-08-16 | ストランド セラピューティクス インコーポレイテッド | 改変ヌクレオチドを含む脂質ナノ粒子 |
| TW202220637A (zh) | 2020-08-06 | 2022-06-01 | 美商現代公司 | 製備脂質奈米顆粒之方法 |
| KR20230129479A (ko) | 2021-01-08 | 2023-09-08 | 스트랜드 세러퓨틱스 인코포레이티드 | 발현 구성체 및 이의 용도 |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
| AU2023262576A1 (en) | 2022-04-26 | 2024-10-10 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
| WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
| WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
| US20250375391A1 (en) | 2022-07-29 | 2025-12-11 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and relates uses |
| CN121079317A (zh) | 2023-04-28 | 2025-12-05 | 深圳深信生物科技有限公司 | 经修饰的递送载体及其应用 |
| WO2024259373A1 (en) | 2023-06-14 | 2024-12-19 | Modernatx, Inc. | Compounds and compositions for delivery of therapeutic agents |
| WO2025160381A1 (en) | 2024-01-26 | 2025-07-31 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
| CN122180503A (zh) | 2024-04-30 | 2026-06-09 | 深圳深信生物科技有限公司 | 脂质纳米颗粒及其应用 |
| ES3048857A1 (es) * | 2024-06-10 | 2025-12-11 | Fundacion Para La Investig E Innovacion Biosanitaria Del Principado De Asturias Finba | FIRMA DE miRNA UTILES EN LA DISCRIMINACION DE TUMORES |
| CN119391860B (zh) * | 2024-12-25 | 2025-03-21 | 慧算基因科技(上海)有限公司 | 一种用于胰腺癌术后mrd检测及动态监测的引物探针组合物、试剂盒及应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005078139A2 (en) * | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| WO2005118806A2 (en) * | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
| JP2009521952A (ja) * | 2006-01-05 | 2009-06-11 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1990A (en) | 1841-02-20 | Head-block of sawmills for sawing without stub-shot and gaging the | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE68921918T2 (de) | 1988-05-09 | 1995-09-07 | Univ Temple | Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten. |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6232068B1 (en) | 1999-01-22 | 2001-05-15 | Rosetta Inpharmatics, Inc. | Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| EP1468110A4 (en) * | 2001-06-10 | 2008-01-30 | Irm Llc | MOLECULAR SIGNATURES NORMALLY TO THE DEATH LEADING CARCINOME |
| EP2428570B1 (en) * | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| JP2005536195A (ja) | 2002-05-31 | 2005-12-02 | ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア | 哺乳動物細胞における効率的なｒｎａ干渉のための方法 |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| ATE334794T1 (de) | 2002-08-21 | 2006-08-15 | Mihaly Rigo | Vorrichtung zum herstellen von rohrverbindungen und rohrverbindung |
| US20050260639A1 (en) * | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
| ATE546528T1 (de) * | 2002-11-13 | 2012-03-15 | Univ Jefferson | Zusammensetzungen und verfahren zur diagnose und behandlung von krebs |
| US7906326B2 (en) * | 2003-05-07 | 2011-03-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US8106180B2 (en) * | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| US20050142581A1 (en) * | 2003-09-04 | 2005-06-30 | Griffey Richard H. | Microrna as ligands and target molecules |
| US20050182005A1 (en) * | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| US7365058B2 (en) * | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
| US20050277139A1 (en) | 2004-04-26 | 2005-12-15 | Itzhak Bentwich | Methods and apparatus for the detection and validation of microRNAs |
| US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| WO2006034387A1 (en) | 2004-09-21 | 2006-03-30 | Applera Corporation | TWO-COLOR REAL-TIME/END-POINT QUANTITATION OF MICRORNAS (miRNAs) |
| GB2480980A (en) * | 2009-03-02 | 2011-12-07 | Trackfive Diagnostics Inc | Methods for predicting cancer response to EGFR inhibitors |
| WO2012083969A2 (en) * | 2010-12-22 | 2012-06-28 | Herlev Hospital | Microrna for diagnosis of pancreatic cancer |
| US9644241B2 (en) * | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
| US20140100124A1 (en) * | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
-
2007
- 2007-03-02 EP EP12168654A patent/EP2522748A1/en not_active Withdrawn
- 2007-03-02 EP EP12168656A patent/EP2522750A1/en not_active Withdrawn
- 2007-03-02 CA CA2638844A patent/CA2638844C/en not_active Expired - Fee Related
- 2007-03-02 JP JP2008557519A patent/JP2009528070A/ja active Pending
- 2007-03-02 AU AU2007223311A patent/AU2007223311C1/en not_active Ceased
- 2007-03-02 WO PCT/US2007/063208 patent/WO2007103808A2/en not_active Ceased
- 2007-03-02 EP EP07757822.7A patent/EP1991706B1/en not_active Not-in-force
- 2007-03-02 US US12/281,194 patent/US20100286232A1/en not_active Abandoned
- 2007-03-02 EP EP12168655A patent/EP2522749A1/en not_active Withdrawn
- 2007-03-02 EP EP12168652A patent/EP2522747A1/en not_active Withdrawn
- 2007-03-02 ES ES07757822.7T patent/ES2448491T3/es active Active
- 2007-03-02 EP EP12168648.9A patent/EP2522746B1/en not_active Ceased
-
2010
- 2010-12-07 US US12/962,065 patent/US20110171646A1/en not_active Abandoned
-
2012
- 2012-08-29 JP JP2012188756A patent/JP5841024B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-08 JP JP2013023199A patent/JP2013081483A/ja active Pending
-
2014
- 2014-04-03 US US14/244,201 patent/US20140357702A1/en not_active Abandoned
-
2017
- 2017-09-05 US US15/695,477 patent/US20180105865A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005078139A2 (en) * | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| WO2005118806A2 (en) * | 2004-05-28 | 2005-12-15 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
| JP2009521952A (ja) * | 2006-01-05 | 2009-06-11 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6012027598; Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ Ｖｏｌ．１０３， Ｎｏ．７, 20060214, ｐ．２２５７-２２６１ * |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020120674A (ja) * | 2012-12-06 | 2020-08-13 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ | Ｃｒｉｓｐｒに基づくゲノム修飾および制御 |
| JP7478772B2 (ja) | 2012-12-06 | 2024-05-07 | シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | Ｃｒｉｓｐｒに基づくゲノム修飾および制御 |
| JP2022115994A (ja) * | 2012-12-06 | 2022-08-09 | シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | Ｃｒｉｓｐｒに基づくゲノム修飾および制御 |
| JP2015107091A (ja) * | 2013-12-05 | 2015-06-11 | 東レ株式会社 | 膵臓がんの検出キット及び検出方法 |
| JP2024075722A (ja) * | 2014-05-30 | 2024-06-04 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| KR102642854B1 (ko) | 2014-05-30 | 2024-03-04 | 국립연구개발법인 고쿠리츠간켄큐센터 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| JP2020188787A (ja) * | 2014-05-30 | 2020-11-26 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| JP2025118849A (ja) * | 2014-05-30 | 2025-08-13 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| JP7687638B2 (ja) | 2014-05-30 | 2025-06-03 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| US12188098B2 (en) | 2014-05-30 | 2025-01-07 | Toray Industries, Inc. | Pancreatic cancer detection kit or device, and detection method |
| JP7082380B2 (ja) | 2014-05-30 | 2022-06-08 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| JPWO2015182781A1 (ja) * | 2014-05-30 | 2017-04-20 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| JP2022122899A (ja) * | 2014-05-30 | 2022-08-23 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| KR102747981B1 (ko) | 2014-05-30 | 2024-12-31 | 국립연구개발법인 고쿠리츠간켄큐센터 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| US11788150B2 (en) | 2014-05-30 | 2023-10-17 | Toray Industries, Inc. | Pancreatic cancer detection kit or device, and detection method |
| KR102594868B1 (ko) | 2014-05-30 | 2023-10-30 | 국립연구개발법인 고쿠리츠간켄큐센터 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| KR20230152169A (ko) * | 2014-05-30 | 2023-11-02 | 도레이 카부시키가이샤 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| KR20240105518A (ko) * | 2014-05-30 | 2024-07-05 | 도레이 카부시키가이샤 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| KR20240034257A (ko) * | 2014-05-30 | 2024-03-13 | 도레이 카부시키가이샤 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| JP7466157B2 (ja) | 2014-05-30 | 2024-04-12 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
| KR20170010856A (ko) * | 2014-05-30 | 2017-02-01 | 도레이 카부시키가이샤 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| KR102680815B1 (ko) | 2014-05-30 | 2024-07-03 | 국립연구개발법인 고쿠리츠간켄큐센터 | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 |
| JP2016123340A (ja) * | 2014-12-26 | 2016-07-11 | 株式会社エバンス | 膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤 |
| US12098430B2 (en) | 2016-03-31 | 2024-09-24 | Toray Industries, Inc. | Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor |
| WO2019117269A1 (ja) | 2017-12-13 | 2019-06-20 | 国立大学法人広島大学 | 膵がんの検出を補助する方法 |
| JP7298914B2 (ja) | 2017-12-13 | 2023-06-27 | 国立大学法人広島大学 | 膵がんの検出を補助する方法 |
| JPWO2019117269A1 (ja) * | 2017-12-13 | 2021-02-18 | 国立大学法人広島大学 | 膵がんの検出を補助する方法 |
| WO2022014670A1 (ja) * | 2020-07-16 | 2022-01-20 | 学校法人 久留米大学 | 膵臓がんのバイオマーカーとしてのマイクロｒｎａの使用 |
| JPWO2022014670A1 (enExample) * | 2020-07-16 | 2022-01-20 | ||
| JP7802367B2 (ja) | 2020-07-16 | 2026-01-20 | 学校法人 久留米大学 | 膵臓がんのバイオマーカーとしてのマイクロｒｎａの使用 |
| US12630881B2 (en) | 2020-07-16 | 2026-05-19 | Kurume University | Use of microRNA as pancreatic cancer biomarker |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2638844A1 (en) | 2007-09-13 |
| JP5841024B2 (ja) | 2016-01-06 |
| AU2007223311A1 (en) | 2007-09-13 |
| CA2638844C (en) | 2016-05-03 |
| AU2007223311B2 (en) | 2012-12-13 |
| US20180105865A1 (en) | 2018-04-19 |
| JP2012231801A (ja) | 2012-11-29 |
| US20140357702A1 (en) | 2014-12-04 |
| EP2522746B1 (en) | 2014-11-12 |
| JP2013081483A (ja) | 2013-05-09 |
| AU2007223311C1 (en) | 2013-06-20 |
| US20110171646A1 (en) | 2011-07-14 |
| WO2007103808A2 (en) | 2007-09-13 |
| ES2448491T3 (es) | 2014-03-14 |
| EP2522748A1 (en) | 2012-11-14 |
| EP2522747A1 (en) | 2012-11-14 |
| EP1991706A4 (en) | 2010-03-17 |
| WO2007103808A3 (en) | 2008-02-28 |
| EP2522749A1 (en) | 2012-11-14 |
| US20100286232A1 (en) | 2010-11-11 |
| EP1991706B1 (en) | 2014-01-15 |
| EP1991706A2 (en) | 2008-11-19 |
| EP2522746A1 (en) | 2012-11-14 |
| EP2522750A1 (en) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5841024B2 (ja) | 膵臓癌に関連するマイクロｒｎａ発現プロファイル | |
| JP5451077B2 (ja) | 肺癌の診断、予後診断及び治療のためのマイクロｒｎａを基盤とした方法及び組成物 | |
| JP5778655B2 (ja) | ヒト巨核球形成間のマイクロｒｎａフィンガープリント | |
| CN103866017B (zh) | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 | |
| EP3048177A1 (en) | Microrna signatures in human ovarian cancer | |
| US20100203544A1 (en) | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER ASSOCIATED CHROMOSOMAL FEATURES | |
| CN105256004A (zh) | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 | |
| AU2016203848B2 (en) | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120829 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121012 |